Hydronidone Phase 2 Trial Shows Improvement in Liver Fibrosis for Chronic Hepatitis B Patients

A phase 2 clinical trial showed that hydronidone led to a notable reversal of liver fibrosis in individuals with chronic hepatitis B (CHB). These findings support the hypothesis that hydronidone can positively impact liver health in patients with this condition. Specifically, the phase 2 trial data indicated a significant improvement in liver fibrosis among CHB patients treated with hydronidone. The investigators, observing the results of the trial, found the findings consistent with their hypothesis regarding the drug’s efficacy.

Newsflash | Powered by GeneOnline AI
Date: April 24, 2025

Related posts:

Breathing Patterns Influence Visual Perception, Study Finds Alarm Raised Over Ultra-Processed Foods Dominating Baby and Toddler Market “Immune Fingerprints” Transform Diagnosis of Complex Diseases Experts Urge Inclusion of Pets in Disease Surveillance Amid Rising H5N1 Cases in Cats

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後